Hypoxia results in upregulation and de novo activation of von willebrand factor expression in lung endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1329-1338

  Mojiri, Anahita ^a   Nakhaii Nejad, Maryam ^a   Phan, Wei Lee ^a   Kulak, Stephen ^a   Radziwon Balicka, Aneta ^a   Jurasz, Paul ^a   Michelakis, Evangelos ^a   Jahroudi, Nadia ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Endothelial cell; Hypoxia; Nuclear factor IB; Von Willebrand factor; YY1

Indexed keywords

CD31 ANTIGEN; TRANSCRIPTION FACTOR YY1; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN; CELL ADHESION; CONTROLLED STUDY; GENE; HEART; HYPOXIA; KIDNEY; LIVER; LUNG; LUNG ALVEOLUS CELL; LUNG ENDOTHELIUM; MICROVASCULAR ENDOTHELIAL CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PULMONARY HYPERTENSION; THROMBOCYTE; TRANSCRIPTION REGULATION; UPREGULATION;

ENDOTHELIAL CELL; HYPOXIA; NUCLEAR FACTOR-IB; VON WILLEBRAND FACTOR; YY1;

ANIMALS; ANOXIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; LAC OPERON; LUNG; MICE; MICE, TRANSGENIC; PHENOTYPE; PROMOTER REGIONS, GENETIC; RANDOM ALLOCATION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 84879091369     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.301359     Document Type: Article

References (50)

1. Sadler JE. von Willebrand factor. J Biol Chem. 1991;266:22777-22780.
2. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative vascular beds. Circ Res. 2007;100:174-190.
3. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. 2007;100:158-173.
4. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem. 2006;54:385-395.
5. Müller AM, Skrzynski C, Nesslinger M, Skipka G, Müller KM. Correlation of age with in vivo expression of endothelial markers. Exp Gerontol. 2002;37:713-719.
6. Müller AM, Skrzynski C, Skipka G, Müller KM. Expression of von Willebrand factor by human pulmonary endothelial cells in vivo. Respiration. 2002;69:526-533.
7. Ochoa CD, Wu S, Stevens T. New developments in lung endothelial heterogeneity: Von Willebrand factor, P-selectin, and the Weibel-Palade body. Semin Thromb Hemost. 2010;36:301-308.
8. Chiurchiu C, Ruggenenti P, Remuzzi G. Thrombotic microangiopathy in renal transplantation. Ann Transplant. 2002;7:28-33.
9. Denis CV. Molecular and cellular biology of von Willebrand factor. Int J Hematol. 2002;75:3-8.
10. Hunt BJ, Lämmle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-Associated haemolytic uraemic syndrome. Thromb Haemost. 2001;85:975-978.
11. Sporn LA, Rubin P, Marder VJ, Wagner DD. Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood. 1984;64:567-570.
12. Verheij M, Dewit LG, Boomgaard MN, Brinkman HJ, van Mourik JA. Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von Willebrand factor. Radiat Res. 1994;137:202-207.
13. Rodeghiero F. von Willebrand disease: still an intriguing disorder in the era of molecular medicine. Haemophilia. 2002;8:292-300.
14. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:3071-3078.
15. Price LC, McAuley DF, Marino PS, Finney SJ, Griffiths MJ, Wort SJ. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2012;302:L803-L815.
16. Lopes AA, Maeda NY. Circulating von Willebrand factor antigen as a predictor of short-term prognosis in pulmonary hypertension. Chest. 1998;114:1276-1282.
17. Lopes AA, Maeda NY, Gonçalves RC, Bydlowski SP. Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J. 2000;139:618-623.
18. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. von Willebrand factor independently predicts longterm survival in patients with pulmonary arterial hypertension. Chest. 2005;128:2355-2362.
19. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109:159-165.
20. Sakamaki F. [Coagulation and fibrinolytic abnormality related to endothelial injury in pulmonary arterial hypertension]. Nihon Rinsho. 2001;59: 1053-1058.
21. Tournier A, Wahl D, Chaouat A, Max JP, Regnault V, Lecompte T, Chabot F. Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension. Thromb Res. 2010;126:-e418-e422.
22. Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood. 2011;117:5033-5043.
23. Aird WC, Edelberg JM, Weiler-Guettler H, Simmons WW, Smith TW, Rosenberg RD. Vascular bed-specific expression of an endothelial cell gene is programmed by the tissue microenvironment. J Cell Biol. 1997;138:1117-1124.
24. Aird WC, Jahroudi N, Weiler-Guettler H, Rayburn HB, Rosenberg RD. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A. 1995;92:4567-4571.
25. Guan J, Guillot PV, Aird WC. Characterization of the mouse von Willebrand factor promoter. Blood. 1999;94:3405-3412.
26. Jahroudi N, Ardekani AM, Greenberger JS. An NF1-like protein functions as a repressor of the von Willebrand factor promoter. J Biol Chem. 1996;271:21413-21421.
27. Jahroudi N, Lynch DC. Endothelial-cell-specific regulation of von Willebrand factor gene expression. Mol Cell Biol. 1994;14:999-1008.
28. Kleinschmidt AM, Nassiri M, Stitt MS, Wasserloos K, Watkins SC, Pitt BR, Jahroudi N. Sequences in intron 51 of the von Willebrand factor gene target promoter activation to a subset of lung endothelial cells in transgenic mice. J Biol Chem. 2008;283:2741-2750.
29. Liu J, Kanki Y, Okada Y, Jin E, Yano K, Shih SC, Minami T, Aird WC. A +220 GATA motif mediates basal but not endotoxin-repressible expression of the von Willebrand factor promoter in Hprt-targeted transgenic mice. J Thromb Haemost. 2009;7:1384-1392.
30. Minami T, Donovan DJ, Tsai JC, Rosenberg RD, Aird WC. Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice. Blood. 2002;100:4019-4025.
31. Nassiri M, Liu J, Kulak S, Uwiera RR, Aird WC, Ballermann BJ, Jahroudi N. Repressors NFI and NFY participate in organ-specific regulation of von Willebrand factor promoter activity in transgenic mice. Arterioscler Thromb Vasc Biol. 2010;30:1423-1429.
32. Peng Y, Jahroudi N. The NFY transcription factor functions as a repressor and activator of the von Willebrand factor promoter. Blood. 2002;99:2408-2417.
33. Peng Y, Jahroudi N. The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem. 2003;278:8385-8394.
34. Schwachtgen JL, Janel N, Barek L, Duterque-Coquillaud M, Ghysdael J, Meyer D, Kerbiriou-Nabias D. Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. Oncogene. 1997;15:3091-3102.
35. Schwachtgen JL, Remacle JE, Janel N, Brys R, Huylebroeck D, Meyer D, Kerbiriou-Nabias D. Oct-1 is involved in the transcriptional repression of the von willebrand factor gene promoter. Blood. 1998;92:1247-1258.
36. Wang X, Peng Y, Ma Y, Jahroudi N. Histone H1-like protein participates in endothelial cell-specific activation of the von Willebrand factor promoter. Blood. 2004;104:1725-1732.
37. Liu J, Yuan L, Molema G, Regan E, Janes L, Beeler D, Spokes KC, Okada Y, Minami T, Oettgen P, Aird WC. Vascular bed-specific regulation of the von Willebrand factor promoter in the heart and skeletal muscle. Blood. 2011;117:342-351.
38. Kawanami O, Jin E, Ghazizadeh M, Fujiwara M, Jiang L, Nagashima M, Shimizu H, Takemura T, Ohaki Y, Arai S, Gomibuchi M, Takeda K, Yu ZX, Ferrans VJ. Heterogeneous distribution of thrombomodulin and von Willebrand factor in endothelial cells in the human pulmonary microvessels. J Nippon Med Sch. 2000;67:118-125.
39. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltagegated potassium channels. Circulation. 2002;105:244-250.
40. Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127:115-125.
41. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479-1491.
42. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res. 2004;95:830-840.
43. King J, Hamil T, Creighton J, Wu S, Bhat P, McDonald F, Stevens T. Structural and functional characteristics of lung macro-And microvascular endothelial cell phenotypes. Microvasc Res. 2004;67:139-151.
44. Hassoun PM, Mouthon L, Barberà JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54:S10-S19.
45. Michelakis ED. Spatio-temporal diversity of apoptosis within the vascular wall in pulmonary arterial hypertension: heterogeneous BMP signaling may have therapeutic implications. Circ Res. 2006;98:172-175.
46. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, Granton J, Stewart DJ. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98:209-217.
47. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26:74-84.
48. de Nigris F, Crudele V, Giovane A, et al. CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. Proc Natl Acad Sci U S A. 2010;107:14484-14489.
49. Grönroos E, Terentiev AA, Punga T, Ericsson J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc Natl Acad Sci U S A. 2004;101:12165-12170.
50. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene. 2006;25:1125-1142.